Context Therapeutics (CNTX) Competitors $0.83 -0.03 (-3.94%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. ORKA, TKNO, TRDA, MREO, HRTX, CYRX, CMPS, OLMA, ARCT, and AURAShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Oruka Therapeutics (ORKA), Alpha Teknova (TKNO), Entrada Therapeutics (TRDA), Mereo BioPharma Group (MREO), Heron Therapeutics (HRTX), Cryoport (CYRX), COMPASS Pathways (CMPS), Olema Pharmaceuticals (OLMA), Arcturus Therapeutics (ARCT), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Oruka Therapeutics Alpha Teknova Entrada Therapeutics Mereo BioPharma Group Heron Therapeutics Cryoport COMPASS Pathways Olema Pharmaceuticals Arcturus Therapeutics Aura Biosciences Oruka Therapeutics (NASDAQ:ORKA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Does the media refer more to ORKA or CNTX? In the previous week, Context Therapeutics had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 6 mentions for Context Therapeutics and 4 mentions for Oruka Therapeutics. Oruka Therapeutics' average media sentiment score of 1.19 beat Context Therapeutics' score of 0.54 indicating that Oruka Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ORKA or CNTX? Context Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOruka TherapeuticsN/AN/A-$5.34M-$5.79-1.58Context TherapeuticsN/AN/A-$23.96M-$0.49-1.70 Do analysts recommend ORKA or CNTX? Oruka Therapeutics presently has a consensus target price of $39.86, suggesting a potential upside of 336.31%. Context Therapeutics has a consensus target price of $6.17, suggesting a potential upside of 642.08%. Given Context Therapeutics' higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Oruka Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Does the MarketBeat Community believe in ORKA or CNTX? Context Therapeutics received 7 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 77.42% of users gave Context Therapeutics an outperform vote. CompanyUnderperformOutperformOruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo VotesContext TherapeuticsOutperform Votes2477.42% Underperform Votes722.58% Do institutionals & insiders believe in ORKA or CNTX? 56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by insiders. Comparatively, 3.0% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ORKA or CNTX more profitable? Oruka Therapeutics' return on equity of -24.96% beat Context Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oruka TherapeuticsN/A -24.96% -21.22% Context Therapeutics N/A -58.76%-55.80% Which has more volatility & risk, ORKA or CNTX? Oruka Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. SummaryOruka Therapeutics beats Context Therapeutics on 10 of the 16 factors compared between the two stocks. Remove Ads Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.54M$6.48B$5.29B$7.37BDividend YieldN/A3.24%5.11%4.31%P/E Ratio-0.916.8321.7017.78Price / SalesN/A228.36378.1494.74Price / CashN/A65.6738.1534.64Price / Book1.125.876.423.98Net Income-$23.96M$142.26M$3.20B$247.33M7 Day Performance22.33%7.58%4.73%4.31%1 Month Performance-1.25%-14.16%-9.88%-7.80%1 Year Performance-40.22%-9.81%10.77%1.40% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics1.4436 of 5 stars$0.83-3.9%$6.17+642.1%-40.7%$74.54MN/A-0.917Gap DownORKAOruka Therapeutics3.0852 of 5 stars$8.14+6.0%$39.86+389.6%N/A$304.77MN/A-1.30N/AUpcoming EarningsNews CoveragePositive NewsTKNOAlpha Teknova1.7761 of 5 stars$5.67+1.4%$8.50+49.9%+122.8%$302.99M$37.75M-7.66240Positive NewsGap UpTRDAEntrada Therapeutics3.1021 of 5 stars$7.92+0.3%$25.67+224.1%-38.2%$297.75M$210.78M4.98110News CoveragePositive NewsMREOMereo BioPharma Group1.854 of 5 stars$1.90-2.6%$7.71+306.0%-20.8%$294.78M$1M-31.6740Gap DownHRTXHeron Therapeutics3.4966 of 5 stars$1.93+1.0%$5.67+193.6%-37.2%$294.00M$144.29M-10.72300Positive NewsCYRXCryoport2.5107 of 5 stars$5.66-1.9%$11.83+109.1%-67.0%$282.49M$228.39M-1.671,020Analyst ForecastCMPSCOMPASS Pathways2.5501 of 5 stars$3.02+6.0%$20.20+568.9%-65.9%$279.87MN/A-1.37120Gap DownOLMAOlema Pharmaceuticals2.7836 of 5 stars$4.06+7.7%$27.67+581.4%-60.6%$277.43MN/A-1.8570Short Interest ↓Positive NewsARCTArcturus Therapeutics3.0614 of 5 stars$10.18+4.9%$59.20+481.5%-65.8%$276.08M$138.39M-4.59180AURAAura Biosciences1.974 of 5 stars$5.45+2.8%$22.75+317.4%-25.6%$273.73MN/A-3.1550Short Interest ↑ Remove Ads Related Companies and Tools Related Companies ORKA Alternatives TKNO Alternatives TRDA Alternatives MREO Alternatives HRTX Alternatives CYRX Alternatives CMPS Alternatives OLMA Alternatives ARCT Alternatives AURA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTX Stock Free CNTX Stock Alerts